Wallace H. Coulter Department of Biomedical Engineering

NUS scientists develop innovative magnetic gel that heals diabetic wounds three times faster

Retrieved on: 
Thursday, October 19, 2023
Wuhan University of Technology, FDA, Engineering, NUS, Connective tissue, Yale-NUS College, Burns, Patent, Hydrogel, Keratinocyte, Orthopedic surgery, National University of Singapore, Agency, Sun, Diabetes, Infection, Nanyang Technological University, Wallace H. Coulter Department of Biomedical Engineering, Sengkang General Hospital, Cell, Fibroblast, Multimedia, Collagen, Quality of life, Tissue, Regeneration, Advanced Materials, Recurrence, Walking, National university, Agency for Science, Technology and Research, Blood, Overalls, Ulcer, Wound healing, Amputation, Patient, Biomedicine, Communication, Consultant, Biomedical engineering, Medical imaging, Electric motor, Nursing, Pharmaceutical industry, Dentistry, Research, Science

SINGAPORE, Oct. 19, 2023 /PRNewswire/ -- Diabetic patients, whose natural wound-healing capabilities are compromised, often develop chronic wounds that are slow to heal. Such non-healing wounds could cause serious infections resulting in painful outcomes such as limb amputation. To address this global healthcare challenge, a team of researchers from the National University of Singapore (NUS) engineered an innovative magnetic wound-healing gel that promises to accelerate the healing of diabetic wounds, reduce the rates of recurrence, and in turn, lower the incidents of limb amputations.

Key Points: 
  • Lab tests showed the treatment coupled with magnetic stimulation healed diabetic wounds about three times faster than current conventional approaches.
  • Furthermore, while the research has focussed on healing diabetic foot ulcers, the technology has potential for treating a wide range of complex wounds such as burns.
  • Chronic diabetic wounds such as foot ulcers (one of the most common and hardest to treat wounds) have therefore become a major global healthcare challenge.
  • While the magnetic wound-healing gel has shown great promise in improving diabetic wound healing, it could also revolutionise the treatment of other complex wound types.

3D Systems’ Extrusion Technology to Produce Patient-specific PEEK Implants Supports Ground-breaking Cranial Surgeries at Leading European Hospitals

Retrieved on: 
Tuesday, October 17, 2023
Acumen, Male, Skull, Wallace H. Coulter Department of Biomedical Engineering, Hospital, Neurosurgery, NYSE, 3D, Stroke, Headache, Biomedical engineering, Craniosynostosis, OMFS, Radiation, DSM-IV codes, Oral and maxillofacial surgery, Health, I4, Polyether ether ketone, Teaching hospital, Anatomy, Medical Device Regulation Act, Decompressive craniectomy, PEEK, ROCK, MDR, 3D Systems, CT, Trauma, POC, MED, Architecture, Dizziness, QMS, Biomedicine, Surgeon, Software, University Hospital of Basel, Hand, Patient, Medical imaging, Medical device, 3D printing

3D Systems’ extrusion printing technology is unique as its architecture and design are easy to use to produce durable, biocompatible implants using Polyetheretherketone (PEEK) material.

Key Points: 
  • 3D Systems’ extrusion printing technology is unique as its architecture and design are easy to use to produce durable, biocompatible implants using Polyetheretherketone (PEEK) material.
  • Additionally, the technology enables the production of patient-specific geometries at the hospital itself providing tremendous benefits to both surgeons and patients.
  • The implant was then produced in the Hospital’s 3D printing lab using VESTAKEEP® i4 3DF PEEK by Evonik on 3D Systems’ EXT 220 MED extrusion platform.
  • The cranial implant was printed using VESTAKEEP® i4 3DF PEEK by Evonik on 3D Systems’ EXT 220 MED extrusion platform.

Enhancing stretchable electronics: NUS researchers develop novel liquid metal circuits for flexible, self-healing wearables

Retrieved on: 
Tuesday, October 3, 2023
Pressure, Communication, Elbow, Advanced Materials, Engineering, Electronics, National University of Singapore, National university, Rehabilitation, Multimedia, Biomedical engineering, Yale-NUS College, Movement, Medial knee injuries, Bilayer, Wallace H. Coulter Department of Biomedical Engineering, Electron energy loss spectroscopy, Biomedicine, Patient, Bitlis, NUS, 3D printing, Consumer electronics

SINGAPORE, Oct. 2, 2023 /PRNewswire/ -- Imagine a stretchable and durable sensor patch for monitoring the rehabilitation of patients with elbow or knee injuries, or an unbreakable and reliable wearable device that measures a runner's cardiac activities during training to prevent life-threatening injuries. Disruptive innovations in wearable technology are often limited by the electronic circuits – which are usually made of conductive metals that are either stiff or prone to damage - that power these smart devices.

Key Points: 
  • Researchers from the National University of Singapore (NUS) have recently invented a new super flexible, self-healing and highly conductive material suitable for stretchable electronic circuitry.
  • The liquid metal circuitry using BiLiSC allows these devices to withstand large deformation and even self-heal to ensure electronic and functional integrity."
  • Prof Lim and his team are also from the Department of Biomedical Engineering under the NUS College of Design and Engineering .
  • The second layer is a composite material containing liquid metal microparticles and it is able to repair itself after breakage.

BioAlberta Annual Achievement Awards

Retrieved on: 
Friday, September 29, 2023
Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Fedora, Mentorship, Doctor of Philosophy, Patient, Aneurysm, Ghana UK-Based Achievement Awards, ALS, Disease, University, Biomedical engineering, Organization, Wallace H. Coulter Department of Biomedical Engineering, Medicine, Chairperson, III, Neurosurgery, Biomarker, History, Thought, Alberta Government Telephones, Blood, Biomedicine, Ecosystem, Joe Byrd (Cherokee Nation Principal Chief), Breast cancer, Pharmaceutical industry, Management, Medical device, Tobacco, Oil

BioAlberta announced the recipients of its 2023 Achievement Awards in recognition of the outstanding contributions of the individuals and companies whose innovation and achievements have contributed to the growing success of Alberta's life sciences sector.

Key Points: 
  • BioAlberta announced the recipients of its 2023 Achievement Awards in recognition of the outstanding contributions of the individuals and companies whose innovation and achievements have contributed to the growing success of Alberta's life sciences sector.
  • The awards were presented at BioAlberta’s 25th Anniversary Health and Life Sciences Showcase & Awards Dinner, held in Edmonton on September 28th.
  • This award acknowledges a company that has shown significant achievement within the marketplace and Alberta’s business community through strong performance or a leadership role.
  • Accepting this award, Dr. Rinker said: “Thank you to BioAlberta, the life sciences community and supporters for this award on the behalf of my entire team.

Cardiost, Inc. Strengthens Scientific Advisory Board with Renowned Cardiovascular Experts, Advances Prototype Development with OEDIT Grant Support

Retrieved on: 
Friday, September 29, 2023
Medical device, University, Heart failure, Interventional cardiology, Lung transplantation, HF, Johnson & Johnson, Clinical trial, Coronavirus Scientific Advisory Board, Research, The Journal of Heart and Lung Transplantation, Biomedical engineering, Universidad, PCI, Harvard Medical School, IMACS, University of Los Andes (Colombia), CO, Journal, Wallace H. Coulter Department of Biomedical Engineering, User experience, Mount Sinai Medical Center, Publication, Biomedicine, MD, Montefiore Medical Center, Cardiology, Universidad de los Andes, Internal medicine, Fort Collins, Colorado, Journal of Cardiac Surgery, LVAD, Ventricular assist device, Hospital, MCS, Massachusetts General Hospital, CFD, Pharmaceutical industry, Heart, Patient

Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.

Key Points: 
  • Cardiost is currently designing an alpha prototype of its LAUD, or Left Atrium Unloading Device, with money it received from Colorado’s OEDIT grant in early 2023.
  • The LAUD is a durable mechanical circulatory support (MCS) device to treat late-stage patients suffering from heart failure (HF).
  • Cardiost is focused on developing cardiovascular devices medical devices in the cardiovascular space.
  • “We are thrilled to add Dr. Goldstein and Dr. Moreno to our Scientific Advisory Board, both KOLs in their respective fields – MCS the former and PCI the latter.

Enrich Biosystems Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery

Retrieved on: 
Monday, August 14, 2023
Emory University, Morgridge Institute for Research, Georgia Tech, Fraunhofer Competence Field Additive Manufacturing, University, University of Puerto Rico at Humacao, NSF, Wallace H. Coulter Department of Biomedical Engineering, National Science Foundation, Cancer, DSM-IV codes, Research, Carol Ann, Biomedical engineering, University of Wisconsin–Madison, Common, Biomedicine, Patient, Cell, Conditional sentence, BioSystems, University of Oregon, Wallace, Kinetics, Pharmaceutical industry

BRANFORD, Conn., Aug. 14, 2023 /PRNewswire-PRWeb/ -- Enrich Biosystems, a pioneering early-stage biotech company developing a unique microfluidics-free cell analysis and isolation technology, today announced it has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT). CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells. Launched in 2017 with investment from NSF, the Center aims to revolutionize the treatment of cancer, heart disease, neurological disorders, and other chronic diseases by enabling the broad use of potentially curative therapies utilizing living cells.

Key Points: 
  • Enrich Biosystems has revolutionized cancer cell therapy discovery with its cutting-edge microfluidics-free technology.
  • Enrich technology simplifies the process of cell co-culturing and kinetics profiling to conduct guided capturing based on cell behaviors and functions.
  • "By partnering with the Enrich team, we aim to improve the current processes of discovery and manufacturing for critical cell therapies.
  • "The Enrich team is thrilled and proud to join the CMaT community," said Dong Wang, CEO at Enrich Biosystems.

ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants

Retrieved on: 
Wednesday, April 19, 2023
Epilepsy, Microelectrode, ASC, University, Inflammasome, AIM2, Associate professor, DSM-IV codes, ME, Quality of life, NLRP3, Dystonia, Biomedical engineering, Essential tremor, Wallace H. Coulter Department of Biomedical Engineering, Parkinson's disease, Biomedicine, Patient, NLRP1, Brain, Invention, NLRC4, Therapy, Disease, Medical imaging, Pharmaceutical industry, Medical device, Biomaterial, Medicine

Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia

Key Points: 
  • Deep brain stimulation devices are intracortical implants used to treat disabling symptoms of neurological conditions such as Parkinson's disease, epilepsy, essential tremor, and dystonia
    WESTON, Fla., April 19, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that world renowned inflammasome researchers and inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100 from the University of Miami Miller School of Medicine have published a scientific paper in the peer-reviewed journal, Biomaterials.
  • In the paper titled, “Activation of inflammasomes and their effects on neuroinflammation at the microelectrode-tissue interface in intracortical implants,” the researchers reported:
    Multiple types of inflammasome sensor molecules (NLRP1, NLRP3, AIM2, and NLRC4) were upregulated following ME implant injury
    NLRP1 and NLRP3, which were upregulated by 48 hours and remained distinctly elevated at 4 weeks, play a vital role in activation of inflammasome complexes during acute and sub-chronic periods following ME-induced injury
    In addition to sensor molecules, ASC and Caspase-1 were persistently elevated throughout the implant duration
    Sustained presence of gasdermin D provides evidence of elevated pyroptosis (“cell death”) occurring at the injury site, which coincided with a decrease in neuronal density
    “Deep brain stimulation is an important therapeutic option to help maintain quality of life in patients with movement disorders whose symptoms are not effectively controlled by medication,” stated Dr. Abhishek Prasad, Associate Professor, the Department of Biomedical Engineering at the University of Miami Miller School of Medicine.
  • “Our results not only demonstrate that continuous activation of inflammasomes contribute to neuroinflammation at the ME-tissue interface, but also reveal the therapeutic potential of targeting inflammasomes to attenuate the foreign body response to cortical implants.”
    “The research published in Biomaterials provides additional support for the therapeutic potential of ZyVersa’s proprietary monoclonal antibody inflammasome ASC inhibitor, IC 100, in neurological injury and disease,” indicated Stephen C. Glover, ZyVersa’s Co-founder, Chairman, CEO and President.
  • “Preclinical studies have demonstrated reduced inflammatory activity and/or improved outcomes in two different models of brain injury, spinal cord injury, age-related inflammation Alzheimer’s disease, and multiple sclerosis.”

Mission Bio Joins NSF Cell Manufacturing Research Initiative to Advance Cell Therapy Development

Retrieved on: 
Tuesday, March 28, 2023
Product management, Emory University, DNA, Morgridge Institute for Research, Georgia Tech, Fraunhofer Competence Field Additive Manufacturing, University, Senior, University of Puerto Rico School of Dental Medicine, NSF, Wallace H. Coulter Department of Biomedical Engineering, National Science Foundation, Gene editing, Cancer, Cell, Biomedical engineering, Disorder, Marketing, University of Wisconsin–Madison, B cell, Common, Biomedicine, Patient, SAN, University of Oregon, Research, Wallace, Safety, Pharmaceutical industry, Vaccine, Tutoring

SOUTH SAN FRANCISCO, Calif., March 28, 2023 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri® Platform to improve analytical assays and cell manufacturing processes. CMaT is a consortium of universities, companies, and clinical collaborators brought together to develop transformative tools and technologies for the consistent, scalable, and low-cost production of high-quality living therapeutic cells.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 28, 2023 /PRNewswire/ -- Mission Bio , the pioneer in high-throughput single-cell DNA and multi-omics analysis, has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri® Platform to improve analytical assays and cell manufacturing processes.
  • Consortium researchers will utilize Tapestri®'s single-cell multi-omics capabilities to streamline and improve analytical assays that are crucial for assessing quality during various stages of the cell therapy development process.
  • Because Tapestri® enables measurement of genotypic and immunophenotypic attributes at single-cell resolution, it will be particularly useful for early cell therapy development to validate cell engineering techniques.
  • "We're proud to join this collaborative effort across various sectors to advance the field of cell therapy from within the community," said Anjali Pradhan, Senior Vice President of Product Management and Marketing at Mission Bio.

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

Retrieved on: 
Tuesday, February 21, 2023
Axitinib, Durability, TKI, University of Arizona College of Medicine – Tucson, Biomedicine, Tissue, Safety, Diabetes, AMD, Patient, Clinical trial, Eye, SCS, University of California, Irvine Medical Center, Biomedical engineering, University, Angiogenesis, Diabetic retinopathy, University of California, Irvine, Visual acuity, Macula, University of Arizona College of Pharmacy, Wallace H. Coulter Department of Biomedical Engineering, UC, Pharming, Biological effects of high-energy visible light, Phase, OASIS, Publication, Pharmaceutical industry, Medical device, Vaccine, Management, Ophthalmology

ALPHARETTA, Ga., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that several presentations were delivered at two prestigious medical conferences in February: the Angiogenesis, Exudation, and Degeneration 2023 meeting and The Macula Society 46th Annual Meeting.  

Key Points: 
  • “Our trial demonstrated that 67% of extension study participants went at least 6 months without needing additional treatment.
  • Clearside’s medical meeting presentations can be accessed on the Company’s Publications and Presentations page.
  • The results from Clearside’s OASIS Phase 1/2a clinical trial were featured.
  • The data presented showed an excellent response to the therapy with 89-100% tumor control, and a favorable safety profile to date.

Phlow Corp. Announces Formation of Business Advisory Board, New Board of Directors Appointment and Corporate President as Company Accelerates Towards Next Stage of Growth

Retrieved on: 
Thursday, February 2, 2023
Curium, Kaleo, Johns Hopkins University, Culture, MD, BD, Biomedical engineering, Hovione, LivaNova, Esperies, Government, Wallace H. Coulter Department of Biomedical Engineering, Doctor of Philosophy, SK, EIT, Health care, Growth, Committee, Knowledge, Executive, Advisory board, Sentara Healthcare, Therapy, Pharmaceutical industry, Management, Phlow, Cambrex Corporation

Tim M. Mayleben, President of two private biopharma companies and board member of Marinus Pharma and Landos Biopharma.

Key Points: 
  • Tim M. Mayleben, President of two private biopharma companies and board member of Marinus Pharma and Landos Biopharma.
  • Previously, long-time CEO of Esperion and board member of LOXO, Vericel and a number of other public and private biopharmaceutical companies.
  • “I am thrilled to announce the formation of the Phlow Business Advisory Board.
  • As a result, and to drive excellence in execution and accelerate growth, Hackman was promoted from Chief Business Officer to President with Edwards remaining CEO.